Contents
Antithrombotic questions on Step 2 CK come in three forms: pick the right class for the clot (arterial or venous, prevention or dissolution), spot the exception (mechanical valve, pregnancy, HIT), or reverse the drug in a bleeding patient. The rule underneath all three: antiplatelets for arterial clots, anticoagulants for venous clots and cardiac emboli, thrombolytics only to dissolve a clot that is causing harm right now.
The pathway: where each drug class acts
- Platelet plugAspirin, P2Y12 inhibitors
- Factor XaApixaban, rivaroxaban, edoxaban, fondaparinux
- Thrombin (IIa)Dabigatran, argatroban, bivalirudin
- Fibrin clotHeparins and warfarin act upstream
- FibrinolysisAlteplase, tenecteplase
Aspirin blocks COX-1; clopidogrel, prasugrel and ticagrelor block the platelet P2Y12 receptor. Unfractionated heparin works through antithrombin on both thrombin and factor Xa, while LMWH acts mostly on Xa. Warfarin lowers the vitamin K-dependent factors II, VII, IX and X, and proteins C and S. Antiplatelets and anticoagulants prevent a clot from forming or growing; neither dissolves a clot that is already there. That is the job of the body's own fibrinolysis, or of a thrombolytic that converts plasminogen to plasmin.
Which class for which clot
| Scenario | Class | First choice | The exception that gets tested |
|---|---|---|---|
| Atrial fibrillation, CHA2DS2-VASc 2 or more in men, 3 or more in women | Anticoagulant | A DOAC over warfarin | Warfarin with a mechanical valve or moderate to severe mitral stenosis; aspirin alone is not stroke prevention |
| Deep vein thrombosis or pulmonary embolism | Anticoagulant | A DOAC, or LMWH bridged to warfarin | Pregnancy: LMWH; warfarin is teratogenic and DOACs are avoided |
| Mechanical heart valve | Anticoagulant | Warfarin | DOACs are harmful here. INR goal 2.5 for an aortic valve without risk factors, 3.0 for a mitral valve or an aortic valve with risk factors |
| Acute coronary syndrome | Antiplatelet plus anticoagulant | Aspirin, a P2Y12 inhibitor and a parenteral anticoagulant | Dual antiplatelet therapy continues after PCI, usually 12 months after ACS |
| STEMI when PCI cannot happen within 120 minutes | Thrombolytic plus antiplatelets and anticoagulant | Fibrinolytic within 30 minutes of arrival | Then transfer for angiography |
| Ischemic stroke within 4.5 hours with a disabling deficit | Thrombolytic | Tenecteplase or alteplase | Mild nondisabling stroke gets aspirin plus clopidogrel for 21 days instead |
| PE with hypotension | Thrombolytic | Systemic alteplase | Normotensive PE gets anticoagulation, even with right ventricular strain |
| Heparin-induced thrombocytopenia | Non-heparin anticoagulant | Argatroban, bivalirudin, fondaparinux or a DOAC | Stop all heparin, including flushes; no warfarin until platelets recover; no platelet transfusion |
| Stable coronary or peripheral artery disease, secondary stroke prevention | Antiplatelet | Aspirin or clopidogrel | Anticoagulants do not replace antiplatelets for arterial plaque |
The bleeding algorithm on an anticoagulant
Based on the 2020 ACC decision pathway for bleeding on oral anticoagulants, updated for the 2025 market change.
- Judge the bleedMajor bleeding means hemodynamic instability, a fall in hemoglobin of 2 g/dL or more, a need for 2 or more units of red cells, or a critical site such as intracranial bleeding.
- Stop the drug and support the patientLocal measures, volume and red cells. Note the last dose time and kidney function, which set how long a DOAC lasts.
- WarfarinIV vitamin K 5 to 10 mg plus 4-factor prothrombin complex concentrate. Plasma only if PCC is unavailable.
- DabigatranIdarucizumab 5 g IV. Dabigatran is also removed by hemodialysis.
- Factor Xa inhibitors4-factor PCC. Andexanet alfa was withdrawn from the US market in December 2025, so it is no longer the answer.
- HeparinProtamine for unfractionated heparin; protamine only partly reverses LMWH.
- RestartOnce bleeding is controlled, weigh restarting: the reason for anticoagulation has not gone away.
Antiplatelet drugs have no specific reversal agent. In spontaneous intracerebral hemorrhage in patients taking antiplatelets, platelet transfusion increased death or dependence in the PATCH trial and is not given routinely.
Reversing a thrombolytic bleed: step by step
Suspect symptomatic intracranial hemorrhage when headache, vomiting, a rising blood pressure or a worse neurologic exam appears within 24 hours of alteplase or tenecteplase.
- Stop the infusionStop alteplase, or a tenecteplase bolus if it is still being given.
- Emergency noncontrast head CTDraw CBC, PT and INR, aPTT, fibrinogen and a type and crossmatch at the same time.
- Cryoprecipitate10 units over 10 to 30 minutes, aiming for a fibrinogen of 150 mg/dL or more. Ten units raise fibrinogen by about 50 mg/dL.
- Or an antifibrinolyticTranexamic acid 1,000 mg IV over 10 minutes, or aminocaproic acid 4 to 5 g over 1 hour, especially when blood products are declined or cryoprecipitate is not available quickly.
- Call for help and control pressureHematology and neurosurgery consults, and supportive care including blood pressure, temperature and glucose control.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| Intracranial bleed on apixaban taken 3 hours ago | Factor Xa inhibitor bleed | 4-factor PCC |
| GI bleed with hypotension on dabigatran | Direct thrombin inhibitor bleed | Idarucizumab |
| INR 6.8 with a large retroperitoneal bleed | Warfarin-associated major bleed | IV vitamin K plus 4-factor PCC |
| Bleeding after a heparin bolus in the cath lab | Unfractionated heparin | Protamine |
| New aphasia worsens and vomiting starts during an alteplase infusion | Thrombolysis-related intracranial hemorrhage | Stop the infusion, emergency CT, cryoprecipitate |
| Platelets fall by half on day 6 of heparin, new DVT | Heparin-induced thrombocytopenia | Stop heparin, start argatroban or another non-heparin agent |
| Atrial fibrillation with a new mechanical mitral valve | Valve thrombosis risk | Warfarin, INR goal 3.0; not a DOAC |
Where students lose points
- Choosing andexanet alfa for a factor Xa inhibitor bleed. It left the US market in December 2025; 4-factor PCC is the answer.
- Giving plasma before PCC for a warfarin bleed. PCC works faster and needs less volume.
- Forgetting vitamin K with PCC. PCC wears off; vitamin K keeps the INR down.
- Prescribing a DOAC for a mechanical valve or for VTE in pregnancy.
- Giving aspirin alone for stroke prevention in atrial fibrillation.
- Thrombolyzing a normotensive PE because the right ventricle looks strained.
- Starting warfarin in acute HIT or transfusing platelets for it.
Practice question
A 76-year-old woman is brought to the emergency department 90 minutes after the sudden onset of headache, left-sided weakness and vomiting. She takes apixaban 5 mg twice daily for atrial fibrillation; her last dose was 3 hours ago. Blood pressure is 182/96 mm Hg and pulse 88/min and irregular. She has a dense left hemiparesis. Noncontrast CT of the head shows a 28-mL right basal ganglia hemorrhage without intraventricular extension. Serum creatinine is 0.9 mg/dL, and the platelet count is 210,000/mm³.
In addition to blood pressure control, which of the following is the most appropriate treatment?
- Andexanet alfa
- Idarucizumab
- Protamine sulfate
- 4-factor prothrombin complex concentrate
- Platelet transfusion
Show the answer
Answer: D. She has an intracerebral hemorrhage on a factor Xa inhibitor taken within the last few hours. With andexanet alfa withdrawn from the US market in December 2025, 4-factor PCC is the reversal strategy.
Why the others are wrong. A: no longer available in the United States. B: idarucizumab reverses dabigatran only. C: protamine reverses heparin, not apixaban. E: her platelet count is normal, and she takes no antiplatelet drug; platelet transfusion does not reverse apixaban.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
1Class for an arterial clot, a venous clot or cardiac embolus, and a clot causing harm right now
Antiplatelet, anticoagulant, thrombolytic.Did you get it?2Warfarin bleed
IV vitamin K plus 4-factor PCC.Did you get it?3Dabigatran bleed
Idarucizumab.Did you get it?4Apixaban or rivaroxaban bleed
4-factor PCC (andexanet withdrawn in the US, December 2025).Did you get it?5Thrombolytic intracranial bleed
Stop the drug, CT, cryoprecipitate 10 units; tranexamic acid as the alternative.Did you get it?6Mechanical valve
Warfarin only, never a DOAC.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review the acute stroke algorithm, or see MedRise for students.
Sources
- Tomaselli GF, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol, 2020 (PubMed 32680646)
- AABB News. AstraZeneca withdraws factor Xa reversal agent from US market. December 23, 2025
- Prabhakaran S, et al. 2026 guideline for the early management of patients with acute ischemic stroke. Stroke, 2026 (PubMed 41582814)
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 2024 (PubMed 38033089)
- Otto CM, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation, 2021 (PubMed 33332150)
- Konstantinides SV, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2020 (PubMed 31504429)
- Cuker A, et al. American Society of Hematology 2018 guidelines: heparin-induced thrombocytopenia. Blood Adv, 2018 (PubMed 30482768)
- Baharoglu MI, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH). Lancet, 2016 (PubMed 27178479)
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



